Thomas T Warner

List of Publications by Year
in descending order

219	13,383	18482 62	26613 107
papers	citations	h-index	g-index

225	225	225	14434
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet, The, 2017, 390, 1664-1675.	13.7	527
2	Hereditary spastic paraplegia: clinical features and pathogenetic mechanisms. Lancet Neurology, The, 2008, 7, 1127-1138.	10.2	481
3	A Tutorial on Lateral Boundary Conditions as a Basic and Potentially Serious Limitation to Regional Numerical Weather Prediction. Bulletin of the American Meteorological Society, 1997, 78, 2599-2617.	3.3	375
4	Psychiatric Symptoms in Huntingtonâ€™s Disease before Diagnosis: The Predict-HD Study. Biological Psychiatry, 2007, 62, 1341-1346.	1.3	363
5	Heterozygous missense mutations in BSCL2 are associated with distal hereditary motor neuropathy and Silver syndrome. Nature Genetics, 2004, 36, 271-276.	21.4	349
6	Genetic and environmental factors in the cause of Parkinson's disease. Annals of Neurology, 2003, 53, S16-S25.	5.3	327
7	Overactive prefrontal and underactive motor cortical areas in idiopathic dystonia. Annals of Neurology, 1995, 37, 363-372.	5.3	299
8	CAGâ€repeat length and the age of onset in Huntington disease (HD): A review and validation study of statistical approaches. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 397-408.	1.7	289
9	Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study. Lancet Neurology, The, 2017, 16, 701-711.	10.2	248
10	Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Annals of Neurology, 2000, 48, 72-76.	5.3	244
11	Diurnal Patterns of Rainfall in Northwestern South America. Part III: Diurnal Gravity Waves and Nocturnal Convection Offshore. Monthly Weather Review, 2003, 131, 830-844.	1.4	243
12	<scp>N</scp>omenclature of genetic movement disorders: <scp>R</scp>ecommendations of the international <scp>P</scp>arkinson and movement disorder society task force. Movement Disorders, 2016, 31, 436-457.	3.9	228
13	Longitudinal change in regional brain volumes in prodromal Huntington disease. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 405-410.	1.9	220
14	Striatal and white matter predictors of estimated diagnosis for Huntington disease. Brain Research Bulletin, 2010, 82, 201-207.	3.0	214
15	Prognosis and Neuropathologic Correlation of Clinical Subtypes of Parkinson Disease. JAMA Neurology, 2019, 76, 470.	9.0	205
16	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nature Genetics, 2021, 53, 294-303.	21.4	198
17	A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 1240-1247.	1.9	196
18	Perrault Syndrome Is Caused by Recessive Mutations in CLPP, Encoding a Mitochondrial ATP-Dependent Chambered Protease. American Journal of Human Genetics, 2013, 92, 605-613.	6.2	186

#	Article	IF	Citations
19	Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity. Human Molecular Genetics, 2000, 9, 2683-2689.	2.9	182
20	Primary dystonia and dystonia-plus syndromes: clinical characteristics, diagnosis, and pathogenesis. Lancet Neurology, The, 2011, 10, 1074-1085.	10.2	178
21	The role of DYT1 in primary torsion dystonia in Europe. Brain, 1998, 121, 2335-2339.	7.6	177
22	Sequence Alterations within CYP7B1 Implicate Defective Cholesterol Homeostasis in Motor-Neuron Degeneration. American Journal of Human Genetics, 2008, 82, 510-515.	6.2	171
23	Association between diabetes and subsequent Parkinson disease. Neurology, 2018, 91, e139-e142.	1.1	171
24	Hereditary spastic paraplegia: from diagnosis to emerging therapeutic approaches. Lancet Neurology, The, 2019, 18, 1136-1146.	10.2	171
25	Genetic and phenotypic characterization of complex hereditary spastic paraplegia. Brain, 2016, 139, 1904-1918.	7.6	170
26	What are the determinants of quality of life in people with cervical dystonia?. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 72, 608-614.	1.9	169
27	Association of Autonomic Dysfunction With Disease Progression and Survival in Parkinson Disease. JAMA Neurology, 2017, 74, 970.	9.0	162
28	Encephalomyelitis in primary hypogammaglobulinaemia. Brain, 1996, 119, 1-15.	7.6	150
29	Dystonia rating scales: Critique and recommendations. Movement Disorders, 2013, 28, 874-883.	3.9	150
30	Cerebral cortex structure in prodromal Huntington disease. Neurobiology of Disease, 2010, 40, 544-554.	4.4	142
31	Diurnal Patterns of Rainfall in Northwestern South America. Part I: Observations and Context. Monthly Weather Review, 2003, 131, 799-812.	1.4	140
32	What sample sizes for reliability and validity studies in neurology?. Journal of Neurology, 2012, 259, 2681-2694.	3.6	140
33	Motor abnormalities in premanifest persons with Huntington's disease: The PREDICTâ€HD study. Movement Disorders, 2009, 24, 1763-1772.	3.9	128
34	Smaller intracranial volume in prodromal Huntington's disease: evidence for abnormal neurodevelopment. Brain, 2011, 134, 137-142.	7.6	118
35	Lamotrigine-induced carbamazepine toxicity: an interaction with carbamazepine-10,11 -epoxide. Epilepsy Research, 1992, 11, 147-150.	1.6	116
36	Developmental regulation of tau splicing is disrupted in stem cell-derived neurons from frontotemporal dementia patients with the 10 + 16 splice-site mutation in MAPT. Human Molecular Genetics, 2015, 24, 5260-5269.	2.9	116

#	Article	IF	Citations
37	A novel RAB7 mutation associated with ulceroâ€mutilating neuropathy. Annals of Neurology, 2004, 56, 586-590.	5.3	112
38	Impact of cervical dystonia on quality of life. Movement Disorders, 2002, 17, 838-841.	3.9	110
39	A partially inactivating mutation in the sodium-dependent lysophosphatidylcholine transporter MFSD2A causes a non-lethal microcephaly syndrome. Nature Genetics, 2015, 47, 814-817.	21.4	108
40	Astrogliopathy predominates the earliest stage of corticobasal degeneration pathology. Brain, 2016, 139, 3237-3252.	7.6	107
41	The Dystonia-associated Protein TorsinA Modulates Synaptic Vesicle Recycling. Journal of Biological Chemistry, 2008, 283, 7568-7579.	3.4	100
42	Capturing the true burden of dystonia on patients. Neurology, 2004, 63, 1629-1633.	1.1	94
43	Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Syndrome. JAMA Neurology, 2020, 77, 377.	9.0	94
44	Creatine therapy for Huntingtonâ€™s disease: Clinical and MRS findings in a 1-year pilot study. Neurology, 2003, 61, 141-142.	1.1	92
45	Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Annals of Neurology, 2000, 48, 72-6.	5.3	92
46	SGCE mutations cause psychiatric disorders: clinical and genetic characterization. Brain, 2013, 136, 294-303.	7.6	91
47	High-dose creatine therapy for Huntington disease: A 2-year clinical and MRS study. Neurology, 2005, 64, 1655-1656.	1.1	87
48	Genetic and clinical heterogeneity in paroxysmal kinesigenic dyskinesia: Evidence for a third EKD gene. Movement Disorders, 2002, 17, 717-725.	3.9	85
49	Nested-Model Simulation of Moist Convection: The Impact of Coarse-Grid Parameterized Convection on Fine-Grid Resolved Convection. Monthly Weather Review, 2000, 128, 2211-2231.	1.4	81
50	The Silver Syndrome Variant of Hereditary Spastic Paraplegia Maps to Chromosome 11q12-q14, with Evidence for Genetic Heterogeneity within This Subtype. American Journal of Human Genetics, 2001, 69, 209-215.	6.2	81
51	Plasma melatonin is reduced in Huntington's disease. Movement Disorders, 2014, 29, 1511-1515.	3.9	81
52	Self-paced timing detects and tracks change in prodromal Huntington disease.. Neuropsychology, 2010, 24, 435-442.	1.3	79
53	A clinical and molecular genetic study of dentatorubropallidoluysian atrophy in four european families. Annals of Neurology, 1995, 37, 452-459.	5.3	78
54	Complex I function in familial and sporadic dystonia. Annals of Neurology, 1997, 41, 556-559.	5.3	78

#	Article	IF	Citations
55	A clinical, genetic and biochemical study of SPG7 mutations in hereditary spastic paraplegia. Brain, 2004, 127, 973-980.	7.6	77
56	Loss of phosphatidylinositol 4-kinase 2Î± activity causes late onset degeneration of spinal cord axons. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 11535-11539.	7.1	77
57	Exclusion of the DYT1 locus in familial torticollis. Annals of Neurology, 1996, 40, 681-684.	5.3	74
58	Early changes in the hypothalamic region in prodromal Huntington disease revealed by MRI analysis. Neurobiology of Disease, 2010, 40, 531-543.	4.4	74
59	Diurnal Patterns of Rainfall in Northwestern South America. Part II: Model Simulations. Monthly Weather Review, 2003, 131, 813-829.	1.4	70
60	Spastin and microtubules: Functions in health and disease. Journal of Neuroscience Research, 2007, 85, 2778-2782.	2.9	70
61	Neuroendocrine abnormalities in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 176-185.	1.9	70
62	A polymorphism in the dopamine receptor DRD5 is associated with blepharospasm. Neurology, 2002, 58, 124-126.	1.1	69
63	Challenges assessing clinical endpoints in early Huntington disease. Movement Disorders, 2010, 25, 2595-2603.	3.9	65
64	PRRT2-related disorders: further PKD and ICCA cases and review of the literature. Journal of Neurology, 2013, 260, 1234-1244.	3.6	63
65	Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study. Lancet Neurology, The, 2021, 20, 107-116.	10.2	62
66	SGCE and myoclonus dystonia: motor characteristics, diagnostic criteria and clinical predictors of genotype. Journal of Neurology, 2014, 261, 2296-2304.	3.6	59
67	Analysis of the ?-sarcoglycan gene in familial and sporadic myoclonus-dystonia: Evidence for genetic heterogeneity. Movement Disorders, 2003, 18, 1047-1051.	3.9	58
68	TorsinA and dystonia: from nuclear envelope to synapse. Journal of Neurochemistry, 2009, 109, 1596-1609.	3.9	58
69	A Systematic Evaluation of Integration Free Reprogramming Methods for Deriving Clinically Relevant Patient Specific Induced Pluripotent Stem (iPS) Cells. PLoS ONE, 2013, 8, e81622.	2.5	57
70	Human spastin has multiple microtubule-related functions. Journal of Neurochemistry, 2005, 95, 1411-1420.	3.9	54
71	Autosomal-dominant dentatorubropallidoluysian atrophy in the United Kingdom. Movement Disorders, 1994, 9, 289-296.	3.9	53
72	DRPLA in Europe. Nature Genetics, 1994, 6, 225-225.	21.4	53

#	Article	IF	Citations
73	The Trail Making Test in prodromal Huntington disease: Contributions of disease progression to test performance. Journal of Clinical and Experimental Neuropsychology, 2011, 33, 567-579.	1.3	52
74	A novel NIPA1 mutation associated with a pure form of autosomal dominant hereditary spastic paraplegia. Neurogenetics, 2005, 6, 79-84.	1.4	51
75	A Histologic Study of the Circadian System in Parkinson Disease, Multiple System Atrophy, and Progressive Supranuclear Palsy. JAMA Neurology, 2018, 75, 1008.	9.0	51
76	Cervical dystonia is associated with a polymorphism in the dopamine (D5) receptor gene. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 71, 262-264.	1.9	50
77	CDIP-58 can measure the impact of botulinum toxin treatment in cervical dystonia. Neurology, 2006, 67, 2230-2232.	1.1	49
78	Mutant torsinA, which causes early-onset primary torsion dystonia, is redistributed to membranous structures enriched in vesicular monoamine transporter in cultured human SH-SY5Y cells. Movement Disorders, 2005, 20, 432-440.	3.9	48
79	The role of torsinA in dystonia. European Journal of Neurology, 2010, 17, 81-87.	3.3	48
80	Increased rate of whole-brain atrophy over 6 months in early Huntington disease. Neurology, 2006, 67, 694-696.	1.1	45
81	Wilsonâ€™s disease: update on pathogenesis, biomarkers and treatments. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1053-1061.	1.9	44
82	A new locus for autosomal recessive complicated hereditary spastic paraplegia (SPG26) maps to chromosome 12p11.1-12q14. Journal of Medical Genetics, 2005, 42, 80-82.	3.2	43
83	White matter DNA methylation profiling reveals deregulation of HIP1, LMAN2, MOBP, and other loci in multiple system atrophy. Acta Neuropathologica, 2020, 139, 135-156.	7.7	42
84	A large family with hereditary spastic paraparesis due to a frame shift mutation of the spastin (SPG4) gene: association with multiple sclerosis in two affected siblings and epilepsy in other affected family members. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 71, 788-791.	1.9	41
85	Myoclonusâ€“dystonia syndrome with severe depression is caused by an exon-skipping mutation in the É›-sarcoglycan gene. Movement Disorders, 2007, 22, 1173-1175.	3.9	41
86	Elevated salivary protein in Parkinson's disease and salivary DJ-1 as aÂpotential marker of disease severity. Parkinsonism and Related Disorders, 2015, 21, 1251-1255.	2.2	41
87	A Metabolic Study of Huntingtonâ€™s Disease. PLoS ONE, 2016, 11, e0146480.	2.5	41
88	Emerging common molecular pathways for primary dystonia. Movement Disorders, 2013, 28, 968-981.	3.9	40
89	CSN complex controls the stability of selected synaptic proteins via a torsinA-dependent process. EMBO Journal, 2011, 30, 181-193.	7.8	39
90	Linkage analysis with chromosome 9 markers in hereditary essential tremor. Movement Disorders, 1993, 8, 374-376.	3.9	38

#	Article	IF	Citations
91	Patient-based outcomes of cervical dystonia: A review of rating scales. Movement Disorders, 2004, 19, 1054-1059.	3.9	38
92	Nonmotor symptoms and focal cervical dystonia: Observations from 102 patients. Basal Ganglia, 2014, 4, 117-120.	0.3	37
93	Clinical manifestations of intermediate allele carriers in Huntington disease. Neurology, 2016, 87, 571-578.	1.1	37
94	Variation at the TRIM11 locus modifies progressive supranuclear palsy phenotype. Annals of Neurology, 2018, 84, 485-496.	5.3	37
95	Clinical presentations of Wilson disease. Annals of Translational Medicine, 2019, 7, S60-S60.	1.7	37
96	Investigation of somatic CNVs in brains of synucleinopathy cases using targeted SNCA analysis and single cell sequencing. Acta Neuropathologica Communications, 2019, 7, 219.	5.2	35
97	An item response analysis of the motor and behavioral subscales of the unified Huntington's disease rating scale in huntington disease gene expansion carriers. Movement Disorders, 2011, 26, 877-884.	3.9	34
98	Identification of candidate cerebrospinal fluid biomarkers in parkinsonism using quantitative proteomics. Parkinsonism and Related Disorders, 2017, 37, 65-71.	2.2	34
99	Linkage analysis in British and French families with idiopathic torsion dystonia. Brain, 1993, 116, 739-744.	7.6	33
100	A Retrospective Evaluation of the Frequency of Impulsive Compulsive Behaviors in Parkinson's Disease Patients Treated with Continuous Waking Day Apomorphine Pumps. Movement Disorders Clinical Practice, 2017, 4, 323-328.	1.5	33
101	A clinical and genetic study of SPG5A linked autosomal recessive hereditary spastic paraplegia. Neurology, 2003, 61, 235-238.	1.1	32
102	Screening of patients with hereditary spastic paraplegia reveals seven novel mutations in theSPG4 (Spastin) gene. Human Mutation, 2003, 21, 170-170.	2.5	31
103	Strategies for treatment of dystonia. Journal of Neural Transmission, 2016, 123, 251-258.	2.8	31
104	Phenotypes, genotypes, and the management of paroxysmal movement disorders. Developmental Medicine and Child Neurology, 2018, 60, 559-565.	2.1	31
105	Hippocampal Î±-synuclein pathology correlates with memory impairment in multiple system atrophy. Brain, 2020, 143, 1798-1810.	7.6	31
106	Youngâ€onset multiple system atrophy: Clinical and pathological features. Movement Disorders, 2018, 33, 1099-1107.	3.9	30
107	Characterization of a novel TYMP splice site mutation associated with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). Neuromuscular Disorders, 2009, 19, 151-154.	0.6	29
108	MIR-NATs repress MAPT translation and aid proteostasis in neurodegeneration. Nature, 2021, 594, 117-123.	27.8	29

#	Article	IF	Citations
109	The role of the alpha -synuclein gene mutation in patients with sporadic Parkinson's disease in the United Kingdom. Journal of Neurology, Neurosurgery and Psychiatry, 1998, 65, 378-379.	1.9	28
110	Early presentation of urinary retention in multiple system atrophy: can the disease begin in the sacral spinal cord?. Journal of Neurology, 2020, 267, 659-664.	3.6	28
111	SPG3A mutation screening in English families with early onset autosomal dominant hereditary spastic paraplegia. Journal of the Neurological Sciences, 2003, 216, 43-45.	0.6	27
112	Colonic transit, high-resolution anorectal manometry and MRI defecography study of constipation in Parkinson's disease. Parkinsonism and Related Disorders, 2019, 66, 195-201.	2.2	27
113	No association with common Caucasian genotypes in exons 8, 13 and 14 of the human cytoplasmic dynein heavy chain gene (DNCHC1) and familial motor neuron disorders. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2003, 4, 150-157.	1.2	26
114	Late onset ataxia: MSAâ€€ or SCA 17? A gene penetrance dilemma. Movement Disorders, 2014, 29, 36-38.	3.9	26
115	Using global team science to identify genetic parkinson's disease worldwide. Annals of Neurology, 2019, 86, 153-157.	5.3	26
116	Review: Clinical, neuropathological and genetic features of Lewy body dementias. Neuropathology and Applied Neurobiology, 2019, 45, 635-654.	3.2	26
117	A Critical Evaluation of Inflammatory Markers in Huntington's Disease Plasma. Journal of Huntington's Disease, 2013, 2, 125-134.	1.9	25
118	Dopamine reuptake transporterâ€“singleâ€photon emission computed tomography and transcranial sonography as imaging markers of prediagnostic Parkinson's disease. Movement Disorders, 2018, 33, 478-482.	3.9	25
119	Analysis of macroautophagy related proteins in G2019S LRRK2 Parkinsonâ€™s disease brains with Lewy body pathology. Brain Research, 2018, 1701, 75-84.	2.2	25
120	Identification of multiple system atrophy mimicking Parkinsonâ€™s disease or progressive supranuclear palsy. Brain, 2021, 144, 1138-1151.	7.6	24
121	Detailed haplotype analysis in Ashkenazi Jewish and non-Jewish British dystonic patients carrying the GAG deletion in the DYT1 gene: evidence for a limited number of founder mutations. Annals of Human Genetics, 1999, 63, 1-8.	0.8	23
122	The BRadykinesia Akinesia INcoordination (BRAIN) Tap Test: Capturing the Sequence Effect. Movement Disorders Clinical Practice, 2019, 6, 462-469.	1.5	23
123	Association of autonomic symptoms with disease progression and survival in progressive supranuclear palsy. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 555-561.	1.9	23
124	Perceptual decision-making in patients with Parkinsonâ€™s disease. Journal of Psychopharmacology, 2014, 28, 1149-1154.	4.0	22
125	A 24-Hour Study of the Hypothalamo-Pituitary Axes in Huntingtonâ€™s Disease. PLoS ONE, 2015, 10, e0138848.	2.5	22
126	Hypothalamic Î±-synuclein and its relation to weight loss and autonomic symptoms in Parkinson's disease. Movement Disorders, 2017, 32, 296-298.	3.9	22

#	Article	IF	Citations
127	Four novel SPG3A/atlastin mutations identified in autosomal dominant hereditary spastic paraplegia kindreds with intraâ€familial variability in age of onset and complex phenotype. Clinical Genetics, 2009, 75, 485-489.	2.0	21
128	Concomitant fragile X-associated tremor ataxia syndrome and Parkinson's disease: a clinicopathological report of two cases: TableÂ1. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 934-936.	1.9	20
129	Central alveolar hypoventilation associated with paraneoplastic brain-stem encephalitis and anti-Hu antibodies. Journal of Neurology, 1994, 241, 561-566.	3.6	19
130	The Cervical Dystonia Impact Profile (CDIP-58): Can a Rasch developed patient reported outcome measure satisfy traditional psychometric criteria?. Health and Quality of Life Outcomes, 2008, 6, 58.	2.4	19
131	Novel clinicopathological characteristics differentiate dementia with Lewy bodies from Parkinsonâ€™s disease dementia. Neuropathology and Applied Neurobiology, 2021, 47, 143-156.	3.2	19
132	Evidence-based guidelines for using the Short Form 36 in cervical dystonia. Movement Disorders, 2007, 22, 122-127.	3.9	18
133	Biallelic variants in TSPOAP1, encoding the active-zone protein RIMBP1, cause autosomal recessive dystonia. Journal of Clinical Investigation, 2021, 131, .	8.2	18
134	Abrogation of LRRK2 dependent Rab10 phosphorylation with TLR4 activation and alterations in evoked cytokine release in immune cells. Neurochemistry International, 2021, 147, 105070.	3.8	18
135	Investigation and management of Wilson's disease: a practical guide from the British Association for the Study of the Liver. The Lancet Gastroenterology and Hepatology, 2022, 7, 560-575.	8.1	18
136	TorsinA and DYT1 dystonia: a synaptopathy?. Biochemical Society Transactions, 2010, 38, 452-456.	3.4	17
137	Lower nucleus accumbens Î±-synuclein load and D3 receptor levels in Parkinson's disease with impulsive compulsive behaviours. Brain, 2019, 142, 3580-3591.	7.6	17
138	Three novel spastin (SPG4) mutations in families with autosomal dominant hereditary spastic paraplegia. Journal of the Neurological Sciences, 2002, 201, 65-69.	0.6	16
139	Comparison of Cumulus Parameterizations and Entrainment Using Domain-Mean Wind Divergence in a Regional Model. Journals of the Atmospheric Sciences, 2004, 61, 1284-1295.	1.7	16
140	Effects of Age and Cognition on a Cross-Cultural Paediatric Adaptation of the Sniffin' Sticks Identification Test. PLoS ONE, 2015, 10, e0131641.	2.5	16
141	The genetic and clinicoâ€pathological profile of earlyâ€onset progressive supranuclear palsy. Movement Disorders, 2019, 34, 1307-1314.	3.9	16
142	Neuroimaging correlates of brain injury in Wilsonâ€™s disease: a multimodal, whole-brain MRI study. Brain, 2022, 145, 263-275.	7.6	16
143	Estimating Premorbid IQ in the Prodromal Phase of a Neurodegenerative Disease. Clinical Neuropsychologist, 2011, 25, 757-777.	2.3	15
144	Fulminant corticobasal degeneration: a distinct variant with predominant neuronal tau aggregates. Acta Neuropathologica, 2020, 139, 717-734.	7.7	15

#	Article	IF	Citations
145	Plasma Neurofilament Light as a Biomarker of Neurological Involvement in Wilson's Disease. Movement Disorders, 2021, 36, 503-508.	3.9	15
146	The Outcome of Dopamine Dysregulation Syndrome in Parkinson's Disease: A Retrospective Postmortem Study. Movement Disorders Clinical Practice, 2018, 5, 519-522.	1.5	14
147	Faster disease progression in Parkinsonâ€™s disease with type 2 diabetes is not associated with increased Î±â€synuclein, tau, amyloidâ€Î² or vascular pathology. Neuropathology and Applied Neurobiology, 2021, 47, 1080-1091.	3.2	14
148	Pathological Relevance of Post-Translationally Modified Alpha-Synuclein (pSer87, pSer129, nTyr39) in Idiopathic Parkinsonâ€™s Disease and Multiple System Atrophy. Cells, 2022, 11, 906.	4.1	14
149	Churgâ€“Strauss syndrome presenting with visual loss. Rheumatology, 2000, 39, 1433-1434.	1.9	13
150	Saccadic Direction Errors are Associated with Impulsive Compulsive Behaviours in Parkinsonâ€™s Disease Patients. Journal of Parkinson's Disease, 2019, 9, 625-630.	2.8	13
151	Chromosomes from the epithelium of plucked human telogen hairs. Human Genetics, 1983, 63, 315-316.	3.8	12
152	Xeroderma pigmentosum is a definite cause of Huntington's diseaseâ€like syndrome. Annals of Clinical and Translational Neurology, 2018, 5, 102-108.	3.7	12
153	The molecular genetics of the dystonias. Journal of Neurology, Neurosurgery and Psychiatry, 1998, 64, 427-429.	1.9	11
154	Silver syndrome is not linked to any of the previously established autosomal dominant hereditary spastic paraplegia loci. American Journal of Medical Genetics Part A, 2001, 102, 68-72.	2.4	11
155	A clinical, genetic and candidate gene study of Silver syndrome, a complicated form of hereditary spastic paraplegia. Journal of Neurology, 2004, 251, 1068-74.	3.6	11
156	Analysis of White Adipose Tissue Gene Expression Reveals CREB1 Pathway Altered in Huntingtonâ€™s Disease. Journal of Huntington's Disease, 2015, 4, 371-382.	1.9	11
157	MSAâ€C or SCA 17? A clinicopathological case update. Movement Disorders, 2016, 31, 1582-1584.	3.9	11
158	Sensitivity and Specificity of the ECAS in Parkinsonâ€™s Disease and Progressive Supranuclear Palsy. Parkinson's Disease, 2018, 2018, 1-8.	1.1	11
159	MOBP and HIP1 in multiple system atrophy: New Î±â€synuclein partners in glial cytoplasmic inclusions implicated in the disease pathogenesis. Neuropathology and Applied Neurobiology, 2021, 47, 640-652.	3.2	11
160	The faecal metabolome and mycobiome in Parkinson's disease. Parkinsonism and Related Disorders, 2022, 95, 65-69.	2.2	11
161	The genetics of Parkinson's disease and parkinsonian syndromes. Journal of Neurology, 1998, 245, 625-633.	3.6	10
162	The dystonias.. Journal of Medical Genetics, 1998, 35, 314-318.	3.2	10

#	Article	IF	Citations
163	Development of parkinsonism after long-standing cervical dystonia â€“ A cohort. Journal of the Neurological Sciences, 2021, 427, 117477.	0.6	10
164	Assembly of Î±-synuclein and neurodegeneration in the central nervous system of heterozygousÂM83 mice following the peripheral administration of Î±-synuclein seeds. Acta Neuropathologica Communications, 2021, 9, 189.	5.2	10
165	In a Rush to Decide: Deep Brain Stimulation and Dopamine Agonist Therapy in Parkinson's Disease. Journal of Parkinson's Disease, 2014, 4, 579-583.	2.8	9
166	Hypokalaemia mimicking Guillain-Barre syndrome.. Journal of Neurology, Neurosurgery and Psychiatry, 1993, 56, 1134-1135.	1.9	8
167	Genetic counselling in mitochondrial diseases. Current Opinion in Neurology, 1997, 10, 408-412.	3.6	8
168	Dystonia: an update on genetics and treatment. Current Opinion in Neurology, 2001, 14, 471-475.	3.6	8
169	Review: Induced pluripotent stem cell models of frontotemporal dementia. Neuropathology and Applied Neurobiology, 2016, 42, 497-520.	3.2	8
170	The neuropsychological profile of Othello syndrome in Parkinson's disease. Cortex, 2017, 96, 158-160.	2.4	8
171	Copy number variation of LINGO1 in familial dystonic tremor. Neurology: Genetics, 2019, 5, e307.	1.9	8
172	DRD1 rare variants associated with tardive-like dystonia: A pilot pathway sequencing study in dystonia. Parkinsonism and Related Disorders, 2014, 20, 782-785.	2.2	7
173	Delineating cerebellar mechanisms in DYT11 myoclonusâ€dystonia. Movement Disorders, 2018, 33, 1956-1961.	3.9	7
174	Neuroimaging Correlates of Cognitive Deficits in Wilson's Disease. Movement Disorders, 0, , .	3.9	7
175	Screening for mutations in the phosphatidylinositol 4-kinase 2-alpha gene in autosomal recessive hereditary spastic paraplegia. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 148-149.	2.1	6
176	Paroxysmal exerciseâ€induced dyskinesia of the hands. Movement Disorders, 2012, 27, 1579-1580.	3.9	6
177	Compulsive sexual behaviour in Parkinsonâ€™s disease is associated with higher doses of levodopa. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1121-1123.	1.9	6
178	Dystonia. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 159, 229-236.	1.8	6
179	Liver transplantation for late-onset presentations of acute liver failure in Wilson's disease: The UK experience over 2 decades. JHEP Reports, 2020, 2, 100096.	4.9	6
180	Elevated 4Râ€tau in astrocytes from asymptomatic carriers of the MAPT 10+16 intronic mutation. Journal of Cellular and Molecular Medicine, 2022, 26, 1327-1331.	3.6	6

#	Article	IF	Citations
181	A large Indian family with rearrangement of chromosome 4p16 and 3p26.3 and divergent clinical presentations. BMC Medical Genetics, 2015, 16, 104.	2.1	5
182	Clinical Heterogeneity in Cerebral Hemiatrophy Syndromes. Movement Disorders Clinical Practice, 2016, 3, 382-388.	1.5	5
183	Epigenomics and transcriptomics analyses of multiple system atrophy brain tissue supports a role for inflammatory processes in disease pathogenesis. Acta Neuropathologica Communications, 2020, 8, 71.	5.2	5
184	Final Exon Frameshift Biallelic PTPN23 Variants Are Associated with Microcephalic Complex Hereditary Spastic Paraplegia. Brain Sciences, 2021, 11, 614.	2.3	5
185	Recent Advances in the Molecular Pathogenesis of Dystonia-Plus Syndromes and Heredodegenerative Dystonias. Current Neuropharmacology, 2013, 11, 30-40.	2.9	4
186	Late Emergence of Parkinsonian Phenotype and Abnormal Dopamine Transporter Scan in Choreaâ€Acanthocytosis. Movement Disorders Clinical Practice, 2015, 2, 182-186.	1.5	4
187	Dystonia. British Medical Bulletin, 2017, 123, 91-102.	6.9	4
188	No evidence of iatrogenic human transmission in autopsy confirmed multiple system atrophy. Movement Disorders, 2018, 33, 1183-1184.	3.9	4
189	Neuropathological progression of clinical Parkinson disease subtypes. Nature Reviews Neurology, 2019, 15, 361-361.	10.1	4
190	Saccadic Bradykinesia in Parkinson's Disease: Preliminary Observations. Movement Disorders, 2021, 36, 1729-1731.	3.9	4
191	Friedreich's ataxia presenting as an isolated spastic paraparesis. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 71, 709-709.	1.9	4
192	Reactivation of tuberculous lymphadenitis during pregnancy. Journal of Infection, 1992, 24, 181-184.	3.3	3
193	The impact of oculomotor functioning on neuropsychological performance in Huntington disease. Journal of Clinical and Experimental Neuropsychology, 2016, 38, 217-226.	1.3	3
194	Iatrogenic B12-deficient peripheral neuropathy following nitrous oxide administration for functional tonic leg spasm: A case report. Clinical Neurology and Neurosurgery, 2017, 160, 108-110.	1.4	3
195	Autonomic Dysfunction in Parkinson's Disease: The Hidden Game Changer?. Movement Disorders, 2018, 33, 1028-1028.	3.9	3
196	The long-term outcome of impulsive compulsive behaviours in Parkinsonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1288-1289.	1.9	3
197	Clinical and pathogenic themes in hereditary spastic paraplegia. Brain, 2020, 143, 2864-2866.	7.6	3
198	A Clinicopathologic Study of Movement Disorders in Frontotemporal Lobar Degeneration. Movement Disorders, 2021, 36, 632-641.	3.9	3

#	Article	IF	Citations
199	Systematic review and metaâ€•analysis of salivary protein concentration in <scp>P</scp>arkinson's disease. Movement Disorders, 2015, 30, 1971-1972.	3.9	2
200	Training in neurology: lessons learnt. Practical Neurology, 2019, 19, 431-437.	1.1	2
201	Hypothalamic Î±-synuclein and its relation to autonomic symptoms and neuroendocrine abnormalities in Parkinson disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2021, 182, 223-233.	1.8	2
202	Neuropsychiatric Features of Punding and Hobbyism in Parkinson's Disease. Movement Disorders Clinical Practice, 2022, 9, 82-86.	1.5	2
203	Do Parkinson's Disease Patients Have Deficits in Sequential Sampling Tasks?. Movement Disorders Clinical Practice, 2014, 1, 325-328.	1.5	1
204	Reply letter to Jinnah â€œLocus pocusâ€•and Albanese â€œComplex dystonia is not a category in the new 2013 consensus classificationâ€• Necessary evolution, no magic!. Movement Disorders, 2016, 31, 1760-1762.	3.9	1
205	Reply to: Youngâ€•onset multiple system atrophy. Movement Disorders, 2018, 33, 1975-1976.	3.9	1
206	Neuropathology of Circadian Alterations in Parkinson Diseaseâ€”Reply. JAMA Neurology, 2019, 76, 115.	9.0	1
207	Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Annals of Neurology, 2000, 48, 72-76.	5.3	1
208	Reply to â€˜Impulse control disorders are associated with lower ventral striatum dopamine D3 receptor availability in Parkinson's disease: A [11C]-PHNO PET study.â€™. Parkinsonism and Related Disorders, 2021, 93, 31-32.	2.2	1
209	REM Sleep Behavior Disorder and Visual Hallucinations in a Pathologically Confirmed Case of Corticobasal Degeneration. Movement Disorders Clinical Practice, 2022, 9, 383-385.	1.5	1
210	Basic genetics for the clinical neurologist. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 73, 5ii-11.	1.9	0
211	The Genetics and Pathogenesis of Dystonia. Blue Books of Neurology, 2010, 34, 457-473.	0.1	0
212	1624â€…Myoclonus dystonia: a clinical and genetic description: Table 1. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, e1.146-e1.	1.9	0
213	ARE PSYCHIATRIC SYMPTOMS A CORE PHENOTYPE OF MYOCLONUS DYSTONIA SYNDROME CAUSED BY SGCE MUTATIONS?. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, e1-e1.	1.9	0
214	DEEP PHENOTYPING OF THE G2019S LRRK2 MUTATION IN PARKINSON'S DISEASE: UCL COHORT. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, e1.16-e1.	1.9	0
215	Author response: Association between diabetes and subsequent Parkinson disease: A record-linkage cohort study. Neurology, 2019, 92, 925-926.	1.1	0
216	The prevalence of impulsive compulsive behaviors in patients treated with apomorphine infusion: a retrospective analysis. Arquivos De Neuro-Psiquiatria, 2021, , .	0.8	0

#	Article	IF	Citations
217	187â€... Variation in training: Results from a survey of UK neurology trainees. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A66.4-A66.	1.9	0
218	109â€... The ABN Acute Neurology Boot Camp: Pre- and post-course feedback for the inaugural event. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A45.2-A45.	1.9	0
219	Somatic copy number variant mutations in alpha-synuclein and genome-wide in brains of synucleinopathy cases. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A4.2-A4.	1.9	0